Treatment of HCV Infection by Targeting MicroRNA

20132,165 citationsJournal Articlebronze Open Access

Authors

Harry L.A. Janssen · Erasmus MC

Hendrik W. Reesink · Academic Medical Center

Eric Lawitz · The University of Texas Health Science Center at San Antonio

Stefan Zeuzem · Goethe University Frankfurt

M. Rodríguez‐Torres · Puerto Rico Community Foundation

Keyur Patel · Duke University

Rozanne C. de Veer

Abstract

The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance. (Funded by Santaris Pharma; ClinicalTrials.gov number, NCT01200420.).

Topics & Keywords

MicroRNA in disease regulation RNA modifications and cancer RNA Research and Splicing

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 18, pp. 1685-1694

DOI: 10.1056/nejmoa1209026

Field-Weighted Citation Impact: 110.01